Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice
Roth, Lynn; Van der Donckt, Carole; Veseli, Besa Emini; Van Dam, Debby; De Deyn, Peter P.; Martinet, Wim; Herman, Arnold G.; De Meyer, Guido R. Y.

Published in:
Vascular pharmacology

DOI:
10.1016/j.vph.2019.05.001

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
https://doi.org/10.1016/j.vph.2019.05.001

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 30-01-2020
Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice

Lynn Roth¹,¹, Carole Van der Donckt²,¹, Besa Emini Veselij, Debby Van Dam³,⁴, Peter P. De Deyn³,⁴, Wim Martinet³, Arnold G. Herman³, Guido R.Y. De Meyer³,⁴,⁎

¹Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium
²Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
³Department of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands
⁴Department of Neurology, Memory Clinic of Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Lindendreef 1, 2020 Antwerp, Belgium

ABSTRACT

Nitric oxide (NO) donors are commonly used for the prevention and treatment of ischemic heart disease. Besides their effects on the heart, NO donors may also prevent hypoxic brain damage and exert beneficial effects on atherosclerosis by favoring features of plaque stability. We recently described that apolipoprotein E (ApoE) deficient mice with a mutation in the fibrillin-1 (Fbn1) gene (ApoE⁻/⁻ Fbn1C1039G⁻/⁻) develop accelerated atherosclerosis, plaque rupture, myocardial infarction, cerebral hypoxia and sudden death. In the present study, we evaluated the effects of chronic treatment with the NO donor molsidomine on atherosclerotic plaque stability, cardiac function, neurological symptoms and survival in the ApoE⁻/⁻ Fbn1C1039G⁻/⁻ mouse model. Female ApoE⁻/⁻ Fbn1C1039G⁻/⁻ mice were fed a Western diet (WD). After 8 weeks of WD, the mice were divided into two groups receiving either molsidomine via the drinking water (1 mg/kg/day; n = 34) or tap water (control; n = 36) until 25 weeks of WD. Survival tended to increase after molsidomine treatment (68% vs. 58% in controls). Importantly, atherosclerotic plaques of molsidomine-treated mice had a thicker fibrous cap (11.1 ± 1.2 vs. 8.1 ± 0.7 μm) and showed an increased occurrence of plaque macrocalcifications (30% vs. 0%), indicative of a more stable phenotype. Molsidomine also improved cardiac function, as fractional shortening was increased (40 ± 2% vs. 27 ± 2%) combined with a decreased end diastolic (3.1 ± 0.2 vs. 3.9 ± 0.2 mm) and end systolic diameter (1.9 ± 0.1 vs. 2.9 ± 0.2 mm). Furthermore, perivascular fibrosis (23 ± 2 vs. 30 ± 2%) and the occurrence of myocardial infarctions (12% vs. 36%) was significantly reduced. Track width, a measure of the animal’s hind limb base of support and representative of hypoxic brain damage, was also normalized as a result of molsidomine treatment (2.54 ± 0.04 vs. 2.91 ± 0.09 cm in controls). These findings demonstrate that the NO donor molsidomine improves cardiac function, reduces neurological symptoms and enhances atherosclerotic plaque stability.

1. Introduction

Nitric oxide (NO) is involved in a wide range of physiological processes in the cardiovascular system [1]. In blood vessels, NO is an important determinant of vascular tone, regulating blood pressure and vascular compliance. Moreover, NO maintains vascular integrity by inhibiting smooth muscle cell (SMC) proliferation, platelet aggregation and leukocyte adhesion to the endothelium [1–3]. In the heart, NO plays a major role in determining the resting vascular tone of coronary resistance vessels [4,5] and is produced in cardiac SMC, where it regulates myocardial contractility [2,5]. Physical or biological injury to the endothelium impairs the production and/or bioavailability of NO, which may play a role in hypertension, repertusion injury, atherosclerosis and myocardial depression [1,6,7].

In line with these findings, patients suffering from ischemic cardiac failure and atherosclerosis might benefit from chronic treatment with an exogenous NO donor. The NO donor molsidomine has the advantage that it releases NO non-enzymatically, avoiding tolerance. Our group and others have previously shown that molsidomine, which exerts its effects through the metabolite 3-morpholinosydnonimine (SIN-1), favoured cardiac function [8–12], decreased platelet aggregation [11,13,14] and signs of oxidative stress and increased features of plaque stability [15] in humans, as well as in animal models. Moreover, patients treated with molsidomine for over a year had significantly lower plasma levels of soluble adhesion molecule ICAM-1, which may slow down the progression of atherosclerosis [16]. However, the beneficial effects of molsidomine are dose-dependent, since high amounts can generate peroxynitrite, causing enhanced oxidative stress, thereby aggravating atherosclerosis [17].

We recently described a novel atherosclerosis model, apolipoprotein E-deficient mice with a mutation in the fibrillin-1 gene (ApoE⁻/⁻ Fbn1C1039G⁻/⁻), characterized by accelerated atherosclerosis, plaque...
rupture, myocardial infarction, cerebral hypoxia and sudden death [18]. In these mice, the elastic fibers in the vessel wall are fragmented, resulting in enhanced arterial stiffness and thereby mimicking vascular aging [19]. As a result, ApoE/−/Fbn1C1039G+/+ mice develop large and highly unstable plaques with a phenotype similar to human plaques. Moreover, these mice develop coronary artery plaques and left ventricular hypertrophy, resulting in decreased cardiac function and myocardial infarction. In the present study, we evaluated the effects of chronic molsidomine treatment in ApoE/−/Fbn1C1039G+/+ mice on atherosclerotic plaque stability, cardiac function, neurological symptoms and sudden death.

2. Methods

2.1. Mice

Female ApoE/−/Fbn1C1039G+/+ mice (n = 70, 6 weeks of age) were fed a Western-type diet (WD; TD88137, Harlan Teklad, Madison, WI) for up to 25 weeks. After 8 weeks of WD feeding, animals were divided into two groups receiving either molsidomine via the drinking water (1 mg/kg body weight/day; n = 34) or tap water (control; n = 36) until 25 weeks of WD. The animals were housed in a temperature-controlled room with a 12-hour light/dark cycle with free access to water and food. Mice were inspected daily for occurrence of sudden death. At the end of the experiment, mice were anesthetized with sodium pentobarbital (75 mg/kg, i.p.) and blood samples were taken from the retro-orbital plexus for plasma cholesterol analysis. Subsequently, animals were euthanized with an overdose of sodium pentobarbital (250 mg/kg, i.p.). Total plasma cholesterol was analysed by means of a commercial kit (Randox, Crumlin, UK). All experiments were approved by the ethical committee of the University of Antwerp and were performed according to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.

2.2. Echocardiography

Transesophageal echocardiograms (ECGs) of ApoE/−/Fbn1C1039G+/+ mice were performed at the start (baseline, 8 weeks on WD) and after 12 weeks of molsidomine treatment. ECGs were performed on anesthetized mice (isoflurane, IsoFlo, Abbott) using a Toshiba diagnostic ultrasound system (SSA-700A), equipped with a 15 MHz transducer.

2.3. Blood pressure

Peripheral blood pressure was measured with a tail cuff (Coda™ High throughput, Kent Scientific, Torrington, CT). Mice were trained for four weeks before the baseline measurement and every week thereafter, until 12 weeks of molsidomine treatment, when a final measurement was performed.

2.4. Motor coordination

Track width was analysed after 12 weeks of treatment as described previously [20]. Briefly, ink was applied to the animals’ hind paws and the mice were required to walk on a strip of paper towards a dark goal box. The median value of a minimum of 10 measurements per mouse was used.

2.5. Histological evaluation

After euthanasia or sudden death, mice were dissected and aorta, heart, spleen and kidneys were weighed (dry weight). Heart and arteries were post-fixed in 4% formaldehyde (pH 7.4) for 24 h, processed and embedded in paraffin. Histological analyses were performed on serial cross sections (5 μm) of the brachiocephalic artery and proximal ascending aorta. The percentage stenosis and the size of atherosclerotic plaques and necrotic cores was measured on hematoxylin and eosin (H & E) stained sections. The necrotic cores were defined as acellular/an-}

3. Results

Body weight and total plasma cholesterol was similar in treated and control mice (Table 1). Survival improved slightly, albeit not significantly, after molsidomine treatment (68% vs. 58% in controls, Table 1). A marked decrease in kidney and spleen weight was observed in the molsidomine-treated group, whereas lung weight remained equal between both groups (Table 1).

3.1. Molsidomine improves atherosclerotic plaque stability

Molsidomine did not affect plaque size in the proximal ascending aorta nor the degree of stenosis in ApoE/−/Fbn1C1039G+/+ mice (Table 2, Fig. S1). Furthermore, the NO donor had no effect on the size of the necrotic core, the amount of macrophages, smooth muscle cells (SMCs),
Data from proximal ascending aorta, mean ± SEM, ECs = endothelial cells.

Atherosclerotic plaque characteristics.

Table 2

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Molsidomine</th>
<th>Molsidomine non calcified</th>
<th>Molsidomine calcified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vessel area (×10³ μm²)</td>
<td>1379 ± 100</td>
<td>1284 ± 117</td>
<td>1399 ± 133</td>
<td>1015 ± 210</td>
</tr>
<tr>
<td>Plaque (%)</td>
<td>798 ± 67</td>
<td>792 ± 73</td>
<td>861 ± 83</td>
<td>630 ± 133</td>
</tr>
<tr>
<td>Stenosis (%)</td>
<td>58 ± 3</td>
<td>62 ± 2</td>
<td>62 ± 3</td>
<td>62 ± 4</td>
</tr>
<tr>
<td>Necrotic core (%)</td>
<td>8.6 ± 1.1</td>
<td>10.1 ± 1.4</td>
<td>10.9 ± 1.9</td>
<td>8.0 ± 1.5</td>
</tr>
<tr>
<td>Macrophages (%)</td>
<td>1.8 ± 0.3</td>
<td>2.7 ± 0.5</td>
<td>2.6 ± 0.6</td>
<td>3.0 ± 0.7</td>
</tr>
<tr>
<td>Total collagen (%)</td>
<td>39.8 ± 1.5</td>
<td>39.7 ± 1.2</td>
<td>38.2 ± 1.5</td>
<td>43.2 ± 1.4</td>
</tr>
<tr>
<td>Type I collagen (%)</td>
<td>3.4 ± 0.4</td>
<td>3.5 ± 0.4</td>
<td>2.8 ± 0.4</td>
<td>5.0 ± 0.5***</td>
</tr>
<tr>
<td>Smooth muscle cells (%)</td>
<td>15.5 ± 1.1</td>
<td>14.2 ± 0.9</td>
<td>13.8 ± 1.3</td>
<td>15.3 ± 0.8</td>
</tr>
<tr>
<td>Fibrous cap thickness (μm)</td>
<td>8.1 ± 0.7</td>
<td>11.1 ± 1.2</td>
<td>10.5 ± 1.3</td>
<td>12.4 ± 2.6</td>
</tr>
<tr>
<td>ICAM-1 positive ECs (%)</td>
<td>94.4 ± 1.5</td>
<td>94.8 ± 1.4</td>
<td>94.5 ± 1.6</td>
<td>95.5 ± 2.8</td>
</tr>
</tbody>
</table>

Survival was evaluated using a Pearson’s chi-square test. Body weight, plasma cholesterol and organ weights are presented as mean ± SEM (n = 13–18 per group) and analysed by an independent samples t-test. *P < 0.05, **P < 0.01 vs. control mice.

Table 1

Characteristics of control and molsidomine-treated ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ mice.

Survival (%) 21/36 (58%) 23/34 (68%)
Body weight (g) 23 ± 1 23 ± 1
Plasma cholesterol (mg/dl) 616 ± 57 621 ± 51
Organ weights (mg)
  Spleen 174 ± 15 107 ± 9**
  Lungs 229 ± 25 219 ± 18
  Kidney 316 ± 23 242 ± 9**

Total collagen, type I collagen and endothelial ICAM-1 expression in the plaque (Table 2, Fig. S1). Nonetheless, the fibrous cap was significantly thicker in molsidomine-treated mice as compared to controls (Table 2, Fig. S1). Molsidomine also induced the formation of intraplaque macrocalcifications, as none of the control mice showed any signs of calcified plaque regions as compared to 30% in the molsidomine-treated mice (Fig. 1). The macrocalcifications were always located at the medial side of the plaque. No signs of calcification were observed in the fibrous cap. The calcified plaques showed a significantly higher type I collagen content as compared to non–calcified plaques of molsidomine-treated mice and controls (Table 2). Furthermore, the calcified plaque area was negatively correlated with plaque size in the proximal ascending aorta (Pearson correlation; R square = 0.868, P = 0.021). Importantly, there was no difference in the percentage of 3-nitrotyrosine, indicative of peroxynitrite–related oxidative stress, in plaques of control and molsidomine-treated mice (Fig. S2). The occurrence of intraplaque neovascularization (control: 83%; molsidomine: 75%), the number of microvessels (control: 4 [0–19]; molsidomine: 3 [0–19]) and the occurrence of hemorrhages in the left common carotid artery (control: 17%; molsidomine: 25%) was not affected by molsidomine treatment.

3.2. Molsidomine reduces cardiac mass and improves cardiac function and left ventricular hypertrophy

Systolic and diastolic peripheral blood pressure did not differ between the molsidomine and control group (Table 3). Echocardiography of the heart revealed a significantly higher fractional shortening (FS) and lower end diastolic diameter (EDD) and end systolic diameter (ESD) in molsidomine-treated mice compared to controls (Fig. 2A–C). Additionally, molsidomine significantly reduced heart mass as compared to the ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ control mice (Fig. 2D).

Track width measurements were previously validated as a reliable marker for hypoxic brain damage in ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ mice [20]. Molsidomine was able to inhibit the increase in track width normally observed in ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ mice fed a WD. Both the median and maximum track width values were significantly lower after 12 weeks of molsidomine treatment compared with control mice (Fig. 3A–B). Track width was also positively correlated with plaque size in the proximal ascending aorta (Fig. 3C).

4. Discussion

The present study confirms the beneficial effects of molsidomine in the treatment of ischemic and left ventricular cardiac failure, as seen in humans [8]. Moreover, molsidomine prevented a loss in motor function and favoured atherosclerotic plaque stability. Molsidomine is a venodilator that reduces the cardiac preload, thereby lowering cardiac output, ventricular work and myocardial oxygen consumption [9]. Furthermore, it evokes a local dilatation of the coronary arteries, reducing coronary artery stenosis and preventing cardiac ischemia [10]. ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ mice are characterized by the development of pronounced atherosclerosis, which is caused by stiffening and inflammation of the arteries, as a result of elastin fragmentation in the vessel wall [18,19]. These mice develop progressive cardiac failure, coronary artery plaque, myocardial infarctions and hypoxic brain damage, similar as seen in humans [18]. Therefore, they could benefit from treatment with an exogenous NO donor. We chose for a chronic treatment with a low dose of molsidomine (1 mg/kg/day). It is very important to select the most optimal dose, because high dosages can generate peroxynitrite, causing enhanced oxidative stress, which may lead to endothelial dysfunction [17]. This was also reported during long-term treatment with other NO donors (nitroglycerin, isosorbide mononitrate) [21]. Therefore, it is important to evaluate 3-nitrotyrosine as a marker of peroxynitrite formation. In the current study, we could not detect a difference between 3-nitrotyrosine in plaques of control and molsidomine-treated mice. Thus, molsidomine at a dose of 1 mg/kg/day does not lead to oxidative stress–related side effects [15].

Importantly, molsidomine significantly improved cardiac function

**Table 3**

Characteristics of control and molsidomine-treated ApoE⁻/⁻ Fbn1¹⁰³⁹G⁻/⁻ mice.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Molsidomine</th>
<th>Molsidomine non calcified</th>
<th>Molsidomine calcified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival (%) 21/36 (58%)</td>
<td>20/36 (58%)</td>
<td>20/34 (58%)</td>
<td>19/35 (55%)</td>
<td>20/34 (58%)</td>
</tr>
<tr>
<td>Body weight (g) 23 ± 1</td>
<td>23 ± 1</td>
<td>23 ± 1</td>
<td>23 ± 1</td>
<td>23 ± 1</td>
</tr>
<tr>
<td>Plasma cholesterol (mg/dl)</td>
<td>616 ± 57</td>
<td>621 ± 51</td>
<td>617 ± 53</td>
<td>620 ± 51</td>
</tr>
<tr>
<td>Organ weights (mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spleen 174 ± 15</td>
<td>107 ± 9**</td>
<td>107 ± 9**</td>
<td>106 ± 9**</td>
<td>107 ± 9**</td>
</tr>
<tr>
<td>Lungs 229 ± 25</td>
<td>219 ± 18</td>
<td>218 ± 18</td>
<td>219 ± 18</td>
<td>220 ± 18</td>
</tr>
<tr>
<td>Kidney 316 ± 23</td>
<td>242 ± 9**</td>
<td>242 ± 9**</td>
<td>241 ± 9**</td>
<td>243 ± 9**</td>
</tr>
</tbody>
</table>

*P < 0.05 vs. control mice.

**§§ P < 0.01 vs. molsidomine non calcified.**
mean ± SEM and were analysed by an Independent samples t-test. Occurrence of MI and coronary plaque were evaluated using a Pearson’s chi-square test. Infarcted area (in mice with coronary plaque) are presented as mean ± SEM (n=13–18 per group) and analysed by Independent samples t-test. **P < 0.01 vs. control mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

![Table 3](image)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Molsidomine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure (mm Hg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP</td>
<td>112 ± 7</td>
<td>111 ± 5</td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>79 ± 7</td>
<td>77 ± 4</td>
</tr>
<tr>
<td>Pulse pressure</td>
<td>35 ± 1</td>
<td>33 ± 2</td>
</tr>
<tr>
<td>Myocardial infarction (MI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occurrence of MI</td>
<td>12/33 (36%)</td>
<td>4/33 (12%)</td>
</tr>
<tr>
<td>Infarcted area (%)</td>
<td>1.8 ± 0.4</td>
<td>1.3 ± 0.5</td>
</tr>
<tr>
<td>Coronary plaque</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occurrence of coronary plaque</td>
<td>15/33 (45%)</td>
<td>14/33 (42%)</td>
</tr>
<tr>
<td>Stenosis (%)</td>
<td>58 ± 9</td>
<td>72 ± 8</td>
</tr>
</tbody>
</table>

Table 3

Blood pressure, MI and coronary artery plaque characteristics.

Blood pressure is presented as mean ± SEM (n = 13–18 per group) and analysed by Independent samples t-test. Occurrence of MI and coronary plaque were evaluated using a Pearson’s chi-square test. Infarcted area (in mice with MI) and coronary stenosis (in mice with coronary plaque) are presented as mean ± SEM and were analysed by an Independent samples t-test.

Therefore NO donors have been investigated as a therapeutic strategy for preventing hypoxic brain damage. For instance, treatment with NO donors prevented hypoxia-ischemia induced neurological damage in rats [23,24] and a reduced brain infarct size was observed in several animal models of stroke [25]. The trials involving the use of molsidomine are limited, but a recent observational study showed that after subarachnoid haemorrhage, molsidomine treatment resulted in less vasospasm-related infarctions and a better clinical outcome [26]. These beneficial effects are not only attributed to the improved cerebral blood flow, but also to other cellular and metabolic effects, such as the inhibition of neuronal apoptosis after ischemia [26]. Thus, the current study further supports the finding that molsidomine treatment can prevent hypoxic brain damage, but further clinical trials are needed to confirm these results.

We also investigated whether molsidomine could have beneficial effects on atherosclerosis. We did not observe a reduction in plaque size nor degree of stenosis, confirming our previous observations [15]. Although macrophage, SMC and total collagen content remained unaltered, the NO donor significantly increased fibrous cap thickness, a major determinant of tensile strength of the cap. NO is able to down-regulate p53 and reduce the expression of pro-inflammatory cytokines IL-1 and TNF-α, thereby decreasing apoptosis and inflammation [27]. In this way, SMC survival is favoured, leading to a thicker fibrous cap and a more stable plaque phenotype. Moreover, molsidomine treatment resulted in a significant increase in plaque macrocalcifications located near the medial border. It is known that calcified coronary nodules are a feature of acute coronary syndromes [28,29]. However, the type of calcification observed in the present study does not resemble calcified nodules since it is not eruptive and does not protrude into the lumen. Furthermore, it is described that coronary artery calcification (CAC) is associated with adverse cardiovascular events in humans, although it is not correlated with plaque vulnerability [30–32]. Importantly, statin therapy increases CAC, which is not related with an increased risk of clinical complications [33–36]. This suggests that the increase in CAC by statin therapy is plaque stabilizing rather than harmful. Thus, there is still no consensus on the impact of calcification on plaque vulnerability and the overall prognosis of cardiovascular disease. In this regard, it is important to differentiate between the presence of microscopic calcifications and macrocalcifications when evaluating the effect on plaque stability. The formation of ‘spotty’ or microscopic calcifications is the result of chronic plaque inflammation characterized by the presence of pro-inflammatory cytokines such as IL-6 and TNF-α [37]. Under these
Fig. 2. Cardiac parameters of control and molsidomine-treated mice. (A–C) ApoE\(^{-/-}\) Fbn\(^{C1039G/+}\) mice treated with molsidomine (n = 9) showed a significantly lower end systolic diameter (ESD) and end diastolic diameter (EDD) as compared to controls (n = 9). Moreover, fractional shortening (FS) was significantly higher in the molsidomine treatment group. Independent samples \(t\)-test; \(\ast\ast\) \(P < 0.01\) and \(\ast\ast\ast\) \(P < 0.001\). (D) Molsidomine treatment normalized heart weight of ApoE\(^{-/-}\) Fbn\(^{C1039G/+}\) mice (n = 15 in both groups). Independent samples \(t\)-test; \(\ast\) \(P < 0.05\). (E) Histological images of Masson’s trichrome stained hearts showing a myocardial infarction (blue staining, arrow) in the right ventricle of the control-treated mouse. Scale bar = 500 \(\mu\)m. (F) Masson’s trichrome staining of coronary arteries indicated that perivascular fibrosis, measured as perivascular collagen area (PVCA) divided by the lumen area (LA), was significantly reduced in molsidomine-treated mice as compared to controls. 2-way ANOVA; \(\ast\ast\) \(P < 0.01\). Scale bar = 100 \(\mu\)m. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
circumstances, remnants of apoptotic SMCs, which remain in the plaque as matrix vesicles, will act as nucleating structures for calcification [38,39]. These microcalcifications are associated with enhanced plaque progression [32] and have the potential to increase the occurrence of plaque rupture via the induction of biomechanical stress [32,40,41]. Considering the latter, the location in the plaque is also of great importance, because only microcalcifications in the fibrous cap negatively affect the mechanical stability, while calcifications found in the necrotic core or at the medial border, as seen in the present study, do not contribute to plaque instability [32,41]. In contrast to microcalcifications, macrocalcifications are considered plaque stabilizing, because they are the result of a healing process that is able to separate the inflammatory plaque content from the vessel lumen [42]. These large calcified areas are formed when the initial inflammation in the plaque is resolved, leading to a tissue repair response and osteogenesis. Therefore, large plaque calcifications have been associated with decreased fibrous cap inflammation [43]. As bone formation is inhibited by chronic inflammation, microcalcifications will not evolve into macrocalcifications, unless the inflammatory status of the plaque decreases [37]. NO has anti-inflammatory properties, which can explain the increase in plaque macrocalcifications [27]. Molsidomine treatment was introduced at a timepoint where advanced atherosclerotic plaques are present in ApoE−/− Fbn1C1039G+/− mice, which is the ideal environment for the development of microcalcifications, but the anti-inflammatory effects of the therapy allowed osteogenesis to occur followed by the formation of macrocalcifications. Moreover, we could detect a clear increase in collagen type I in the calcified plaques, which is also a typical hallmark of a healing response after inflammation and further stabilizes the atherosclerotic plaque. All these data indicate that molsidomine treatment is able to favour plaque stability in advanced atherosclerosis.

Interestingly, we also observed a lower spleen and kidney weight, indicative of decreased inflammation. Other research groups have demonstrated that molsidomine was able to reduce kidney weight [12], which was attributed to the anti-inflammatory and local dilating effects of NO. [44] In addition, molsidomine modulates inflammation in various conditions such as muscular atrophy [45,46], wound healing [47] and bacterial inflammation [48].

In conclusion, we demonstrated that administration of the NO donor molsidomine improves heart function, reduces neurological signs and enhances atherosclerotic plaque stability in a mouse model of vulnerable plaque and spontaneous myocardial infarction. The effect of molsidomine treatment on the phenotype of rupture-prone plaques in mice is new and might offer opportunities to further investigate the use of NO donors in atherosclerotic plaque stabilization and the prevention of cardiac and cerebral ischemia.

Sources of funding

This work was financially supported by the Agency for Innovation by Science and Technology (IWT), the Fund for Scientific Research (FWO)-Flanders, the University of Antwerp (BOF), agreement between Institute Born-Bunge and University of Antwerp, the Medical Research Foundation Antwerp, and Neurosearch Antwerp. Besa Emini Veseli is a PhD fellow of the Horizon 2020 program of the European Union - Marie Skłodowska-Curie Actions, Innovative Training Networks (ITN), Call: H2020-MSCA-ITN-2015, NUMBER — 675,527 — MOGLYNET.

Declaration of interest

None.

Acknowledgements

The authors would like to thank Bronwen Martin for critically reviewing the manuscript and Rita Van den Bossche, Hermine Fret, Anne-Elise Van Hoydonck, Sanne Lauryssen, Michiel Knaapen and Anne-Sophie Hervent for their valuable assistance.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vph.2019.05.001.

References


A. Sarem, G. Bahn, P.D. Reaven, V. Investigators, Progression of vascular calcification is increased with statin use in the veterans affairs diabetes trial (VADIT), Diabetes Care 35 (2012) 2199–2392.


